Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 11.76
-3.33 %
$ 758 M
Market Cap
-14.33
P/E
1. INTRINSIC VALUE
Balance Sheet
Evolus, Inc.
| Current Assets | 151 M |
| Cash & Short-Term Investments | 87 M |
| Receivables | 47.7 M |
| Other Current Assets | 16.7 M |
| Non-Current Assets | 81.2 M |
| Long-Term Investments | 0 |
| PP&E | 10.4 M |
| Other Non-Current Assets | 70.8 M |
| Current Liabilities | 63 M |
| Accounts Payable | 9.24 M |
| Short-Term Debt | 1.72 M |
| Other Current Liabilities | 52 M |
| Non-Current Liabilities | 164 M |
| Long-Term Debt | 122 M |
| Other Non-Current Liabilities | 42.6 M |
EFFICIENCY
Earnings Waterfall
Evolus, Inc.
| Revenue | 266 M |
| Cost Of Revenue | 84 M |
| Gross Profit | 182 M |
| Operating Expenses | 217 M |
| Operating Income | -34.4 M |
| Other Expenses | 16 M |
| Net Income | -50.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Evolus, Inc.
| Net Income | -50.4 M |
| Depreciation & Amortization | 6.02 M |
| Capital Expenditures | -1.47 M |
| Stock-Based Compensation | 22.3 M |
| Change in Working Capital | 0 |
| Others | 4.17 M |
| Free Cash Flow | -19.5 M |
Wall Street Analysts Price Targets
Evolus, Inc.
Wall Street analysts predict an average 1-year price target for EOLS of $24 , with forecasts ranging from
a
low of
$20 to a high of $27 .
EOLS Lowest Price Target
Wall Street Target
20 USD
70.07%
EOLS Average Price Target
Wall Street Target
24 USD
104.08%
EOLS Highest Price Target
Wall Street Target
27 USD
129.59%
4. DIVIDEND
ANALYSIS
EOLS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Evolus, Inc.
Sold
0-3 MONTHS
2.16 M USD 5
3-6 MONTHS
156 K USD 3
6-9 MONTHS
138 K USD 2
9-12 MONTHS
6.19 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based.
businesswire.com
- 2 weeks ago
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 2 weeks ago
Evolus to Report First Quarter Financial Results on May 7, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To par.
businesswire.com
- 3 weeks ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant d.
businesswire.com
- 1 month ago
Evolus Announces Commercial Launch of Evolysse™
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for health.
businesswire.com
- 1 month ago
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™, a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural.
businesswire.com
- 1 month ago
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here.
businesswire.com
- 1 month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement d.
businesswire.com
- 1 month ago
Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Gangireddy Madhumitha - Stryker Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon, everyone, and thank you for standing by.
seekingalpha.com
- 2 months ago
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago.
zacks.com
- 2 months ago
Evolus posts quarterly profit on strong sales of cosmetic injection
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.
reuters.com
- 2 months ago
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. “We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%,” said David Moatazedi, President and Chief Executive Officer of Ev.
businesswire.com
- 2 months ago
8. Profile
Summary
Evolus, Inc. EOLS
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 758 M
Dividend Yield
0.00%
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Contact
520 Newport Center Drive, Newport Beach, CA, 92660
https://www.evolus.com
IPO
Date
Feb. 8, 2018
Employees
332
Officers
Mr. Jeffrey J. Plumer
General Counsel
Mr. David Moatazedi
President, Chief Executive Officer & Director
Ms. Sandra Beaver
Chief Financial Officer
Mr. Nareg Sagherian
Head of Global Investor Relations & Corporate Communications
Mr. Kurt Knab
Senior Vice President of Sales
Ms. Jessica Novak
Senior Vice President of Human Resources
Ms. Tomoko Yamagishi-Dressler
Chief Marketing Officer
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.
Chief Medical Officer and Head of Research & Development